ASPIRIN THERAPY FOR PRIMARY VERSUS SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: AN UPDATED META-ANALYSIS.  by Das, Jayanta Robert et al.
A140.E1316
JACC March 9, 2010
Volume 55, issue 10A
 QUALITY OF CARE AND OUTCOMES ASSESSMENT 
ASPIRIN THERAPY FOR PRIMARY VERSUS SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE: 
AN UPDATED META-ANALYSIS.
ACC Poster Contributions
Georgia World Congress Center, Hall B5
Monday, March 15, 2010, 3:30 p.m.-4:30 p.m.
Session Title: Comparative Effectiveness Studies
Abstract Category: Outcomes Assessment
Presentation Number: 1195-173
Authors: Jayanta Robert Das, Shervin Eshaghian, George A. Diamond, P.K. Shah, Sanjay Kaul, Cedars Sinai Medical Center, Los Angeles, CA
Background: Current guidelines recommend aspirin (ASA) for primary prevention of heart disease (men) and stroke (women) in those above 
moderate risk for cardiovascular disease (CVD). We compared the strength of evidence regarding ASA for primary versus secondary prevention.
Methods: We updated the 2009 ATT-C meta-analysis for ASA in primary prevention by adding results from the POPADAD, JPAD, and AAA trials 
conducted in high-risk diabetic and vascular disease populations. Pooled estimates for relative risk of outcomes were derived via a fixed-effects 
Mantel Haenszel model. Heterogeneity was assessed via Cochran’s Q test. The benefit-risk balance was estimated by deriving NNT (number needed 
to treat) and NNH (number needed to harm). 
Results: 104,331 and 18,249 patients were analyzed for primary and secondary prevention, respectively. Pooled data revealed a statistically 
significant reduction in serious vascular events and nonfatal MI in both groups. However, a statistically significant reduction in nonfatal stroke, and 
cardiac death was found only in secondary prevention. Increased rates of major extracranial bleed were found in both groups.The NNT and NNH 
were desirable (NNT<<NNH) for secondary, but not primary prevention.
Conclusions: The benefit of ASA appears to substantially outweigh the risk for secondary, but not primary prevention. These results challenge the 
current guidelines and suggest that routine use of ASA for primary prevention may not be justified even in high-risk populations.
Event
Aspirin
(%/yr)
Control
(%/yr)
Risk ratio
(95%CI)
P value
Heterogeneity 
P value
NNT or
NNH (-)
Primary prevention (9 trials, N=104,331)
Serious vascular event 0.57 0.63 0.90 (0.85, 0.96) 0.001 0.51 1668
Nonfatal MI 0.21 0.25 0.82 (0.74, 0.90) <0.001 0.43 2500
Nonfatal CVA 0.18 0.20 0.92 (0.83, 1.03) 0.15 0.71 5000
CHD death 0.12 0.12 0.99 (0.87, 1.13) 0.91 0.10 71
Major extracranial bleed 0.11 0.08 1.47 (1.26, 1.71) <0.001 0.13 -3333
Hemorrhagic stroke 0.04 0.03 1.26 (0.97, 1.64) 0.08 0.60 -10000
Secondary prevention (16 trials, N=18,249)
Aspirin
(%/yr)
Control
(%/yr)
Risk ratio
(95%CI)
P value
Heterogeneity 
P value
NNT or
NNH
Serious vascular event 6.69 8.19 0.81 (0.75, 0.87) <0.001 0.2 67
Nonfatal MI 1.60 2.30 0.69 (0.60, 0.80) <0.001 0.5 143
Nonfatal CVA 2.13 2.60 0.81 (0.71, 0.92) <0.001 0.1 213
CHD death 2.73 3.07 0.87 (0.78, 0.98) 0.007 0.4 294
Major extracranial bleed 0.25 0.06 2.69 (1.25, 5.76) 0.002 0.1 -526
